Safety and Efficacy of Cannabis in Tourette Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-15

Study Completion Date

2020-01-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For many individuals with Tourette syndrome (TS), available medications do not help with their symptoms, or cause significant side effects. Two small controlled trials have investigated the effect of oral delta-9-tetrahydrocannabinol (THC), a principal psychoactive ingredient of cannabis, in TS patients. While these trials have shown promising results, the effect sizes were not as large and consistent as those reported by patients with regards to inhaled cannabis (smoked or vaporized). Indeed, based on anecdotal evidence, patients have much greater improvement in their symptoms using inhaled cannabis than using cannabinoid pharmaceuticals. However, there have been no controlled trials of inhaled medical cannabis for TS to date. Furthermore, various medical cannabis products are authorized in Canada with different contents of THC and cannabidiol (CBD), another primary cannabinoid. No data exists regarding the dosing, efficacy and safety of these products in the treatment of TS. To gather such data, a double-blind, randomized, crossover pilot trial will be conducted to compare the efficacy and safety of three vaporized medical cannabis products with different THC and CBD contents, as well as placebo, in adults with TS. As well, the PK/PD profile of THC and CBD of the products will be assessed and correlated with tic symptoms

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder

NCT00231985

Tourette Syndrome Tic Disorders

COMPLETED PHASE2

Evaluation of a Cognitive Psychophysiological Treatment for Tourette Syndrome and Tic Disorders

NCT03225430

Tic Disorder, Chronic Motor or Vocal Tourette Syndrome in Children Tourette Syndrome

COMPLETED NA

Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine

NCT02289248

Depression

COMPLETED PHASE1

Investigating Distress Tolerance in Adults With Tourette Syndrome

NCT05047705

Tourette Syndrome Tic Disorders Tics

COMPLETED NA

An Electronic Intervention to Reduce Cannabis Among Young Adults in Psychiatric Care

NCT04174963

Cannabis Use Psychiatric Disorder

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tourette Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

There are four treatment schemes. All subjects will be randomized in a 1:1:1:1 ratio to one of the four treatment schemes. Participants will receive a single dose of each of the 3 cannabis products + placebo, with the order determine by their assigned treatment arm.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

The participants, investigators and analysts will be masked as to the treatment arm and product of each participant and visit. Only the pharmacists will be aware of the strain.

Intervention Type DRUG

THC 0.6%, CBD 14%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabis

THC 10%, CBD \<0.5%

Intervention Type DRUG

Cannabis

THC 8.6%, CBD 8.6%

Intervention Type DRUG

Cannabis

THC 0.6%, CBD 14%

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Marijuana Marijuana Marijuana

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female adult, 18-65 years of age (inclusive) at the time of signing the informed consent.
* The subject meets current DSM-5 diagnostic criteria for TS\[6\], diagnosed by a neuropsychiatrist with expertise in TS and related conditions.
* YGTSS-TTS ≥16, frequency subscore = 5 and intensity subscore ≥ 2. In addition, tic free intervals do not last more than two minutes based on both self-reporting and observation by clinician at both screening and Week 0 (randomization). This requirement is for the purpose of minimizing the potential for floor effects given the relatively short window for assessing effect on symptoms in this single-dose trial.
* The subject is able and willing to refrain from using any non-study cannabis during the screening and treatment phases of the study.
* Females of childbearing potential (defined by menarche and not having undergone surgical sterilization/hysterectomy) must have a negative pregnancy test, must be practicing acceptable double-barrier methods of contraception (or can confirm abstinence at each scheduled visit), and must not be breast feeding.
* Written informed consent must be obtained from the subject prior to the initiation of any protocol-required procedures.
* The subject is able to comprehend and satisfactorily comply with the protocol requirements.

Exclusion Criteria

* • The subject and/or his/her family have a history of psychosis, schizophrenia or bipolar disorder.

* Sexually active females of childbearing potential who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial; Females who are breast-feeding and/or who have a positive serum pregnancy test result prior at the time of screening.
* The subject represents a significant risk of committing suicide (current suicide plan or attempt in past 2 years) or committing homicide.
* The subject has a history of serious head injury, seizure disorder, or developmental delay (intelligence quotient≤85).
* The subject has either of: cardiovascular disease; respiratory disease such as chronic obstructive pulmonary disease (COPD) or lung cancer (asthma is not an exclusionary criterion); hepatitis.
* The subject has a current or past history of substance abuse within the last 5 years, with the exception of cannabis.
* The subject is using cannabis regularly for the treatment of TS.
* The subject has any abnormal laboratory tests and vital sign results which in the investigator's judgment is medically significant and would impact the safety of the subject or the interpretation of the study results.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No